Asia stymies Columvi's expansion
Starglo isn't applicable to a US population, an adcom rules.
Starglo isn't applicable to a US population, an adcom rules.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Conference activity picks up, with the big one – ASCO – at the end of the month.